The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.

06/16/2026, 8:45 AM • Benzinga

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Recursion Pharmaceuticals, an AI-focused biotech company, has hit a 52-week low despite partnerships with major pharmaceutical companies and Nvidia. While the company's AI-powered drug discovery platform shows promise and addresses a real problem in drug development costs and timelines, it lacks tangible clinical evidence. With no approved products and only early-stage pipeline candidates, the stock remains highly speculative and risky for most investors.

05/25/2026, 7:30 PM • The Motley Fool

Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight

The AI in life sciences market is projected to grow from USD 2.2 billion in 2025 to USD 11.5 billion by 2034, driven by accelerated drug discovery, precision medicine adoption, and increasing healthcare data availability. North America leads with 44.78% market share, while Europe and Asia-Pacific show significant growth potential. Major pharmaceutical and technology companies are investing heavily through partnerships and AI-enabled platforms.

05/13/2026, 1:00 PM • GlobeNewswire

3 Stocks Poised to Disrupt the Healthcare Market by 2030

The healthcare industry is shifting toward data-driven, precision medicine models powered by AI and genomic data. Three companies are positioned to lead this transformation: Tempus AI is building a healthcare data platform with network effects; Recursion Pharmaceuticals is accelerating drug discovery through automation and machine learning; and Axsome Therapeutics is gaining traction with fast-acting CNS treatments, particularly its antidepressant Auvelity.

05/08/2026, 7:30 AM • The Motley Fool

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Citeline and its parent company Norstella announced an expanded partnership with Recursion (NASDAQ: RXRX) to integrate real-world data and evidence capabilities into Recursion's drug discovery and development platform. The collaboration aims to improve trial design, site selection, and development decisions, with Recursion reporting 30-60% improvements in enrollment through the integrated ClinTech platform.

03/31/2026, 9:00 AM • GlobeNewswire

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

AI stocks have suffered significant corrections as investors reassess the technology's real-world value and cost-effectiveness. The article argues this represents the 'trough of disillusionment' phase of the Gartner Hype Cycle, which historically precedes a bullish recovery. The author recommends Oracle and Alphabet as well-positioned to capitalize on the upcoming 'slope of enlightenment' phase, while cautioning against Microsoft despite its current dominance.

03/22/2026, 1:27 PM • The Motley Fool

ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025

ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.

02/24/2026, 3:52 PM • Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday as all three growth stocks trade significantly below their 2025 highs. Figma showed strong Q4 results with 40% revenue growth and improved margins, while CoreWeave benefits from AI infrastructure demand. Recursion faces headwinds after Nvidia exited its stake, though the company remains a clinical-stage AI-driven biotech play.

02/22/2026, 10:02 AM • The Motley Fool

Can This Beaten-Down AI Stock Bounce Back in 2026?

Recursion Pharmaceuticals, an AI-focused biotech company, experienced significant stock declines last year. While the company expects clinical trial data readouts in 2026, these will be early-stage phase 1 results unlikely to move the stock meaningfully. The company faces increasing competition from well-resourced rivals like Eli Lilly and has yet to prove its AI-driven drug development approach works or achieve any approved products, making it a highly risky investment.

01/28/2026, 9:01 PM • The Motley Fool

Why Recursion Pharamaceuticals Topped the Market Today

Recursion Pharmaceuticals reported positive results from a phase 1b/2 clinical trial for REC-4881, a drug targeting familial adenomatous polyposis. The trial showed 75% of participants experienced polyp burden reduction, validating the company's AI-assisted drug discovery platform.

12/08/2025, 5:10 PM • The Motley Fool

Is Recursion Pharmaceuticals a Meme Stock?

Jim Cramer labeled Recursion Pharmaceuticals a meme stock, but evidence suggests otherwise. The biotech company uses AI for drug discovery, has promising partnerships, but remains a speculative and risky investment with no market products.

11/19/2025, 8:13 AM • The Motley Fool

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Recursion Pharmaceuticals uses AI for drug discovery, aiming to reduce drug development time and costs. Despite ambitious claims, the company faces significant financial challenges, including substantial losses and ongoing cash burn.

10/31/2025, 6:15 AM • The Motley Fool

Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares

Christopher Gibson, CEO of Recursion Pharmaceuticals, sold 100,000 shares worth approximately $604,000, representing about 9.49% of his direct holdings. The transaction reflects ongoing stock sales and potential challenges in the company's drug development strategy.

10/20/2025, 12:07 PM • The Motley Fool

Is Recursion Pharmaceuticals a Millionaire Maker?

Recursion Pharmaceuticals is an AI-powered 'TechBio' company using artificial intelligence to accelerate drug discovery and development, with promising clinical-stage programs in cancer and rare diseases, and partnerships with major pharmaceutical companies.

10/16/2025, 9:31 AM • The Motley Fool